Welcome to LookChem.com Sign In|Join Free
  • or
n-4-pentenyl (2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(1->2)-[(3,4,6-tri-O-benzyl-2-O-pivaloyl-β-D-galactopyranosyl)-(1->4)]-3,6-di-O-benzyl-α-D-mannopyranoside is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

351011-63-7

Post Buying Request

351011-63-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

351011-63-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 351011-63-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,0,1 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 351011-63:
(8*3)+(7*5)+(6*1)+(5*0)+(4*1)+(3*1)+(2*6)+(1*3)=87
87 % 10 = 7
So 351011-63-7 is a valid CAS Registry Number.

351011-63-7Downstream Products

351011-63-7Relevant academic research and scientific papers

Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine

Hewitt,Seeberger

, p. 4233 - 4243 (2001)

The synthesis of a potential carbohydrate vaccine for the parasitic disease leishmaniasis is described. New solution- and solid-phase synthetic strategies were explored for the assembly of a unique tetrasaccharide antigen found on the Leishmania lipophosphoglycan. An initial solution-phase synthesis relied on thioglycosides as building blocks and the establishment of the central disaccharide from lactal via an oxidation-reduction sequence. A second approach was completed both in solution and on solid support. The solid-phase synthesis relied on assembly from monosaccharide units and was used to evaluate different glycosylating agents in the efficient installation of the galactose β-(1-4) mannoside. Glycosyl phosphates proved most successful in this endeavor. This first solid-phase synthesis of the Leishmania cap provided rapid access to the tetrasaccharide in 18% overall yield while requiring only a single purification step. The synthetic cap tetrasaccharide was conjugated to the immunostimulator Pam3Cys to create fully synthetic carbohydrate vaccine 1 and to the carrier protein KLH to form semisynthetic vaccine 2. Currently, both constructs have entered initial immunological experiments in mice targeted at the development of a vaccine against the parasitic disease leishmaniasis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 351011-63-7